Hikma Pharmaceuticals (OTCMKTS:HKMPF) Upgraded at Barclays

Hikma Pharmaceuticals (OTCMKTS:HKMPF) was upgraded by research analysts at Barclays from a “strong sell” rating to a “hold” rating in a report issued on Tuesday, Zacks reports.

Separately, Citigroup reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, August 12th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Hikma Pharmaceuticals Price Performance

HKMPF opened at $22.19 on Tuesday. The business has a fifty day simple moving average of $21.52 and a 200 day simple moving average of $19.63. Hikma Pharmaceuticals has a 1 year low of $16.34 and a 1 year high of $25.34. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.06 and a current ratio of 1.82.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.